Whom and Where Are We Not Vaccinating? Coverage after the Introduction of a New Conjugate Vaccine against Group A Meningococcus in Niger in 2010
Whom and Where Are We Not Vaccinating? Coverage after the Introduction of a New Conjugate Vaccine against Group A Meningococcus in Niger in 2010
复制标题
DOI：
10.1371/journal.pone.0029116
复制
发表时间：
2012-01-20
期刊：
影响因子：
3.7
通讯作者：
Wierzba, Thomas F.
中科院分区：
文献类型：
--
作者：
Kim, Sung Hye;Pezzoli, Lorenzo;Wierzba, Thomas F.
MenAfriVac是针对非洲“脑膜炎带”开发的针对脑膜炎奈瑟菌血清群A的新型结合疫苗。在尼日尔，2010年9月和12月，针对蒂拉贝里、尼亚美和多索地区3 135 942名1至29岁的人开展了MenAfriVac推广运动的前两个阶段。我们评估了这场运动，并确定了蒂拉贝里和尼亚美地区哪些亚群或地区的疫苗接种覆盖率较低。在Filingue区进行的第一阶段之后，我们使用30615个整群抽样调查和整群样本中的巢式批次质量保证（LQA）分析来估计覆盖率，以确定哪些亚群（按年龄1-14/15-29和性别定义）的疫苗接种覆盖率不可接受（
MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the African "meningitis belt". In Niger, the first two phases of the MenAfriVac introduction campaign were conducted targeting 3,135,942 individuals aged 1 to 29 years in the regions of Tillaberi, Niamey, and Dosso, in September and December 2010. We evaluated the campaign and determined which sub-populations or areas had low levels of vaccination coverage in the regions of Tillaberi and Niamey. After Phase I, conducted in the Filingue district, we estimated coverage using a 30615 cluster-sampling survey and nested lot quality assurance (LQA) analysis in the clustered samples to identify which subpopulations (defined by age 1-14/15-29 and sex) had unacceptable vaccination coverage (